Luye Pharma Group Ltd Asset Resilience Ratio
Luye Pharma Group Ltd asset resilience ratio. Luye Pharma Group Ltd (LUP) has an Asset Resilience Ratio of 9.15% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LUP cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Luye Pharma Group Ltd (2016–2025)
Asset resilience ratio of Luye Pharma Group Ltd from 2016 to 2025. This chart shows how Luye Pharma Group Ltd's Asset Resilience Ratio has changed over time. Read Luye Pharma Group Ltd (LUP) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Luye Pharma Group Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Luye Pharma Group Ltd (LUP) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €3.00 Billion | 9.15% |
| Total Liquid Assets | €3.00 Billion | 9.15% |
Asset Resilience Insights
- Limited Liquidity: Luye Pharma Group Ltd maintains only 9.15% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Luye Pharma Group Ltd Industry Peers by Asset Resilience Ratio
Compare Luye Pharma Group Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
Luye Pharma Group Ltd Asset Resilience Ratio by Year (2016–2025)
Luye Pharma Group Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Luye Pharma Group Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.15% | €3.00 Billion ≈ $3.51 Billion |
€32.83 Billion ≈ $38.38 Billion |
+3.86pp |
| 2024-12-31 | 5.29% | €1.57 Billion ≈ $1.83 Billion |
€29.61 Billion ≈ $34.62 Billion |
-5.96pp |
| 2023-12-31 | 11.25% | €2.87 Billion ≈ $3.35 Billion |
€25.49 Billion ≈ $29.80 Billion |
-2.03pp |
| 2022-12-31 | 13.28% | €3.22 Billion ≈ $3.77 Billion |
€24.25 Billion ≈ $28.35 Billion |
-0.32pp |
| 2021-12-31 | 13.60% | €3.07 Billion ≈ $3.59 Billion |
€22.58 Billion ≈ $26.40 Billion |
+6.13pp |
| 2020-12-31 | 7.47% | €1.54 Billion ≈ $1.80 Billion |
€20.63 Billion ≈ $24.12 Billion |
-7.35pp |
| 2019-12-31 | 14.82% | €2.86 Billion ≈ $3.35 Billion |
€19.31 Billion ≈ $22.58 Billion |
-3.36pp |
| 2018-12-31 | 18.19% | €3.19 Billion ≈ $3.73 Billion |
€17.54 Billion ≈ $20.50 Billion |
-5.75pp |
| 2017-12-31 | 23.93% | €2.58 Billion ≈ $3.01 Billion |
€10.76 Billion ≈ $12.58 Billion |
-1.59pp |
| 2016-12-31 | 25.52% | €2.35 Billion ≈ $2.75 Billion |
€9.21 Billion ≈ $10.76 Billion |
-- |
About Luye Pharma Group Ltd
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and X… Read more